The Effect of Disease Modifying Treatment In Multiple Sclerosis Patients

At AAN 2017, Robert Zivadinov, MD, PhD, Professor of neurology, University at Buffalo, discussed the primary findings in the phase 3 randomized, placebo controlled TOPIC study, which focused really on the differences between the two doses (7 and 14mg) of Aubagio and placebo.